1
|
The Future of T2DM Management:
Addressing Disease Pathophysiology
and Targeting Global Cardiometabolic Risk
Supported by an educational grant from
Amylin Pharmaceuticals, Inc. and Lilly USA, LLC |
 |
|
2 |
Advances in Basal Insulin:
Addressing the Barriers to Initiation
& Intensification of Diabetes Therapy
Supported by an educational grant from
Novo Nordisk, Inc. |
|
 |
| 3 |
Overcoming Today’s Top Challenges to Effective Screening, Diagnosis,
& Management of Patients with Severe
or Familial Hypercholesterolemia:
Expert Recommendations &
Interactive Case Review
Supported by an educational grant from
Genzyme Corporation |
|
|
4 |
New Paradigms for Targeting A1C
and Global Cardiometabolic Risk: Expert Recommendations for Optimizing GLP-1 Analogs in the T2DM Continuum of Care
Supported by an educational grant from
Novo Nordisk, Inc. |
|
|
| 5 |
Antiplatelet Therapy 2011: Clinical Challenges & Expert Recommendations
for State-of-the-Art Treatment of Patients with ACS Undergoing PCI
Supported by an educational grant from
Daiichi Sankyo, Inc. and Eli Lilly and Company |
|
|
6 |
A New Pathway Ahead:
Targeting the Kidney in the
Management of Patients with T2DM
Supported by an educational grant from
Bristol-Myers Squibb and AstraZeneca LP |
|
|
| 7 |
Stable Ischemic Heart Disease 2011: Appreciating the Impact of Patient Variations & Comorbidities on
Clinical Decision Making
Supported by an independent educational grant from Gilead Sciences Medical Affairs |
|
|
8 |
Vasodilating Beta Blockers:
A New Generation of Options
for Targeting Endothelial Dysfunction, Hypertension & Global CV Risk
Supported by an educational grant from
Forest Laboratories, Inc. |
|
|
| 9 |
Statin Therapy in Clinically Complex Patients: Expert Recommendations
& Evidence-Based Strategies
for Achieving Optimal Results
Supported by an educational grant from
Kowa Pharmaceuticals America, Inc. and Lilly USA, LLC |
|
|
10 |
Targeting Triglycerides:
Current Challenges and Emerging Options for Cardiovascular Risk Reduction
Supported by an educational grant from
Amarin Corporation |
|
|
| 11 |
Early Diagnosis & Treatment of PAH: Evidence-Based Strategies
& Expert Recommendations
for Improving Patient Outcomes
Supported by an educational grant from
Actelion Pharmaceuticals US, Inc. |
|
|
|
|
|
